CheezhengTTM(SZ:002287)2025-04-24 10:35Company Milestones and Achievements - Tibet Cheezheng Tibetan Medicine Co., Ltd. has completed three significant milestones in its 30-year history, including being the first company to invest in poverty alleviation in Tibet and becoming a leader in the modernization of Tibetan medicine[5]. - The company has been recognized as a national-level high-tech enterprise and has won multiple awards, including the "2024 Golden Single Product" for over-the-counter drugs[41]. - The company has achieved significant brand recognition, being ranked 2nd in the bone injury category for OTC products in China and 28th in the top 100 Chinese traditional medicine companies[54]. - The core product, the pain relief patch, ranks first in the market share among external patches for musculoskeletal diseases in urban pharmacies[43]. - The company has established a comprehensive treatment model for musculoskeletal disorders, integrating various dosage forms such as patches and ointments[43]. Product Development and Innovation - The company has developed innovative products such as the pain relief patch, which combines traditional Tibetan medicine with advanced modern formulation techniques, enhancing product quality and patient experience[6]. - The company focuses on the development of traditional Tibetan medicine, with a product line that includes external pain relief and oral Tibetan medicines[44]. - The company is actively conducting evidence-based medical research to optimize product indications and enhance brand marketing[43]. - The company has successfully registered multiple products, including the Renqing Mangjue capsule and the Honghua Ruyi pill, which have received national recognition and patents[6]. - The company aims to modernize Tibetan medicine through research and development, focusing on unmet clinical needs and internationalization strategies[50]. Financial Performance - The company's operating revenue for 2024 reached ¥2,337,969,652.39, representing a 14.32% increase compared to ¥2,045,152,409.09 in 2023[26]. - The net profit attributable to shareholders for 2024 was ¥582,281,116.79, a slight increase of 0.19% from ¥581,198,850.19 in 2023[26]. - The net profit after deducting non-recurring gains and losses was ¥425,808,626.27, which is a 15.09% increase from ¥369,978,084.82 in 2023[26]. - The total assets at the end of 2024 were ¥6,790,420,367.07, reflecting a 7.81% increase from ¥6,298,478,593.58 at the end of 2023[26]. - The basic earnings per share for 2024 was ¥1.0981, a marginal increase of 0.08% from ¥1.0972 in 2023[26]. Market Expansion and Strategy - The company is focused on expanding its market reach beyond Tibet, leveraging its unique product offerings to meet diverse healthcare needs globally[9]. - The company has identified over 600 high-potential counties across more than 2,000 counties and cities nationwide, penetrating over 70% of high-potential markets[57]. - The company plans to enhance its marketing capabilities across various channels, including retail and e-commerce, while promoting its brand through academic and digital marketing strategies[131]. - The company is positioned to benefit from the increasing demand for healthcare due to the aging population and rising chronic disease rates[37]. - The company is leveraging modern technology to innovate and modernize traditional Tibetan medicine, aligning with national policies promoting the integration of digital health[37]. Social Responsibility and Cultural Heritage - The company has a strong commitment to social responsibility, being listed in the "Excellent Cases of Social Responsibility of Private Enterprises in China (2023)"[41]. - The company emphasizes the importance of cultural heritage and innovation in its operations, establishing connections with contemporary Tibetan medicine masters and organizing development conferences[7]. - The company is actively involved in cultural preservation and charitable initiatives, reflecting its commitment to social responsibility[174]. - The company launched the "Qixin Guardian" public welfare initiative, reaching 160 million people with the integrated solution for musculoskeletal pain[67]. Governance and Management - The company maintains a strong independent operational structure, ensuring no interference from controlling shareholders in decision-making[146]. - The board of directors consists of 7 members, with 4 external directors, including 3 independent directors, ensuring effective separation between management and operations[147]. - The company has established a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders and regulatory bodies[151]. - The company has a performance assessment system for its directors and senior management, linking remuneration to company performance[178]. - The company has a dedicated human resources department that operates independently from the controlling shareholders, ensuring autonomous recruitment and management[154]. Research and Development - The company’s R&D team is engaged in evidence-based medicine research, collaborating with national key specialty research teams[61]. - Research and development expenses increased by 13.82% to ¥66,730,503.64, indicating a focus on innovation and product development[95]. - The company is currently conducting Phase III clinical trials for several new drug applications, aiming to enhance its product pipeline and market competitiveness[94]. - The company is focusing on enhancing its research and development quality and speed through collaboration with CROs and internal audits[140]. - The company plans to deepen the application of AI technology in training programs by 2025 to support high-quality development[192]. Marketing and Sales - The company has established a digital marketing management system to enhance decision-making efficiency through big data analysis[57]. - The sales team consists of over 1,700 members, utilizing a multi-channel marketing approach to expand market reach across various medical fields[52]. - The company has seen significant growth in online sales channels, particularly in B2C and O2O sales[65]. - The company emphasizes digital marketing transformation to capture the trend of online consumer behavior and enhance brand visibility[52]. - The company has achieved a significant increase in international sales, which rose by 290.86% to ¥3,171,745.33, compared to ¥811,470.98 in the previous year[83]. Investment and Financial Management - The total investment amount for the reporting period was CNY 2,506,703,904.11, representing a 67.96% increase compared to CNY 1,492,430,000.00 in the same period last year[106]. - The company issued 4,100,000 shares at a price of CNY 11.81 per share, raising a total of CNY 48,421,000, with a net amount of CNY 45,120,010 after deducting issuance costs[114]. - The company has not engaged in any securities or derivative investments during the reporting period[110][111]. - The company has established independent financial management systems and operates separate bank accounts, ensuring financial autonomy[158]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 17.976 million[178].